User login
Key clinical point: Treating skin manifestations with biologics significantly reduced the risk of developing psoriatic arthritis (PsA) in patients with psoriasis.
Major finding: The risk of developing PsA was significantly higher in patients who did not receive treatment with biologics vs. the biological treatment group (adjusted hazard ratio 1.39; 95% CI 1.03-1.87).
Study details: Findings are from a retrospective cohort including 1,326 patients with psoriasis without PsA, of which 663 patients received biological treatment and 663 patients did not receive biological treatment.
Disclosures: This study did not report any external funding. Dr. Pavlovsky declared serving as investigator, advisor, consultant, and invited lecturer for various sources.
Source: Rosenthal YS et al. Arthritis Rheumatol. 2021 Aug 23. doi: 10.1002/art.41946.
Key clinical point: Treating skin manifestations with biologics significantly reduced the risk of developing psoriatic arthritis (PsA) in patients with psoriasis.
Major finding: The risk of developing PsA was significantly higher in patients who did not receive treatment with biologics vs. the biological treatment group (adjusted hazard ratio 1.39; 95% CI 1.03-1.87).
Study details: Findings are from a retrospective cohort including 1,326 patients with psoriasis without PsA, of which 663 patients received biological treatment and 663 patients did not receive biological treatment.
Disclosures: This study did not report any external funding. Dr. Pavlovsky declared serving as investigator, advisor, consultant, and invited lecturer for various sources.
Source: Rosenthal YS et al. Arthritis Rheumatol. 2021 Aug 23. doi: 10.1002/art.41946.
Key clinical point: Treating skin manifestations with biologics significantly reduced the risk of developing psoriatic arthritis (PsA) in patients with psoriasis.
Major finding: The risk of developing PsA was significantly higher in patients who did not receive treatment with biologics vs. the biological treatment group (adjusted hazard ratio 1.39; 95% CI 1.03-1.87).
Study details: Findings are from a retrospective cohort including 1,326 patients with psoriasis without PsA, of which 663 patients received biological treatment and 663 patients did not receive biological treatment.
Disclosures: This study did not report any external funding. Dr. Pavlovsky declared serving as investigator, advisor, consultant, and invited lecturer for various sources.
Source: Rosenthal YS et al. Arthritis Rheumatol. 2021 Aug 23. doi: 10.1002/art.41946.